114 research outputs found
Estimation, Validation and Uncertainty of the Position of the Separatrix Contour at ASDEX Upgrade
Rapport fait au nom de la commission du marché intérieur sur les propositions de la Commission de la C.E.E. au Conseil relatives à , I, une directive concernant la réalisation de la liberté d'établissement et de la libre prestation des services pour les activités non salariées relevant du commerce de détail (groupe ex 612 CITI) (doc. 48-I), II, une directive relative aux modalités des mesures transitoires dans le domaine des activités non salariées relevant du commerce de détail (groupe ex 612 CITI) (doc.48 - II). Documents de Séance 1965-1966, Document 85, 25 Aout 1965. = Report on behalf of the Committee on Internal Market on the proposals of the EEC Commission to the Council for, I, a Directive on the attainment of freedom of establishment and freedom to provide services for self-employed activities under retail trade (ISIC group ex 612) (doc. 48-I), II, a directive on procedures for transitional measures in the field of self-employment within the retail (ISIC group ex 612) (doc.48 - II). Working Documents 1965-1966, Document 85, 25 August 1965
Rapport fait au nom de la Commission prevue a l'article 4 paragraphe 1 du reglement du Parlement europeen sur la reclamation deposee par lettre du 7 mars 1966. Documents de Seance 1966-1967, Document 64, 11 Mai 1966. = "Report on behalf of the Commission provided for in Article 4 Paragraph 1 of the Rules of the European Parliament on the claim filed by letter of 7 March 1966. Working Documents 1966-1967, Document 64, 11 May 1966"
Rapport fait au nom de la commission du marche interieur sur la proposition de la Commission de la C.E.E. au Conseil (doc. 85, 1964-1965) relative a une directive concernant la realisation de la liberte d'etablissement et de la libre prestation des services pour les activites non salariees relevant des branches electricite, gaz, eau et services sanitaires (branche 5 C.I.T.I.). Documents de seance 1965-1966, Document 32, 10 Mai 1965. = "Report on behalf of the Committee on Domestic Market on the proposal of the EEC Commission to the Council (Doc. 85, 1964-1965) on a directive concerning the realization of the freedom of establishment and freedom to provide services for non-wage workers activities such as electricity, gas, water and sanitary services (ISIC Division 5). Working Documents 1965-1966, Document 32, 10 May 1965"
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphomaâa long-term follow-up study
Background High-dose chemotherapy followed by autologous stem-cell transplantation (HCT-ASCT) is a promising approach in eligible patients with primary central nervous system lymphoma (PCNSL). We report long-term data of patients who were treated according to HCT-ASCT containing protocols. Patients and methods We analyzed survival and relapse rates in 43 (<67 years) immunocompetent patients with newly diagnosed PCNSL being treated according to two different high-dose methotrexate-based protocols followed by high-dose carmustine/thiotepa (BCNU/TT) plus ASCT (±whole brain irradiation). Analysis was conducted for all patients (intention-to-treat) and those patients who actually received HCT-ASCT (per-protocol). Results Thirty-four patients achieved complete remission, of those 12 relapsed (35%), while 6 of them relapsed 5 years after diagnosis. After a median follow-up of 120 months, median overall survival (OS) was reached after 104 months. Two- and 5-year OS was 81% and 70% and 2- and 5-year event-free survival (EFS) was 81% and 67%, respectively. In per-protocol analysis (N=34), 5-year OS and EFS was 82% and 79%, respectively. HCT-ASCT associated related mortality was not observed. Conclusions Sequential high-dose MTX containing chemotherapy followed by high-dose carmustine/thiotepa plus ASCT (±whole brain irradiation) is safe and leads to high survival rates in eligible patients with newly diagnosed PCNS
Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer
BACKGROUND: Resection of liver metastases from colorectal cancer (CRC) in the oligometastatic stage improves survival and is a potentially curative treatment. Thus, predictive scores that reliably identify those patients who especially benefit from surgery are essential. PATIENTS AND METHODS: In this multicenter analysis, 512 patients had undergone surgery for liver metastases from CRC. We investigated distinct cancer-specific risk factors that are routinely available in clinical practice and developed a predictive preoperative score using a training cohort (TC), which was thereafter tested in a validation cohort (VC). RESULTS: Inflammatory response to the tumor, a right-sided primary tumor, multiple liver metastases, and node-positive primary tumor were significant adverse variables for overall survival (OS). Patients were stratified in five groups according to the cumulative score given by the presence of these risk factors. Median OS for patients without risk factors was 133.8 months [95% confidence interval (CI) 81.2-not reached (nr)] in the TC and was not reached in the VC. OS decreased significantly for each subsequent group with increasing number of risk factors. Median OS was significantly shorter (P < 0.0001) for patients presenting all four risk factors: 14.3 months (95% CI 10.5 months-nr) in the TC and 16.6 months (95% CI 14.6 months-nr) in the VC. CONCLUSIONS: Including easily obtainable variables, this preoperative score identifies oligometastatic CRC patients with prolonged survival rates that may be cured, and harbors potential to be implemented in daily clinical practice
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphomaâa randomized phase III trial (MATRix)
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)âa systematic review and individual patient data meta-analysis
Evidence for prognosis and treatment of elderly patient with primary central nervous system is limited. High-dose methotrexate should be applied whenever possible, especially combination with oral alkylating agents is a promising approach. Further combinations with other intravenous drugs do not seem to improve outcome. More prospective trials designed for elderly PCNSL patients are warrante
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice
The MATRix chemoimmunotherapy regimen is highly effective in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system (PCNSL). However, nothing is known about its feasibility and efficacy in everyday practice, where patients are more often older/frailer than those enrolled in clinical trials. We conducted a retrospective study addressing tolerability/efficacy of MATRix in 156 consecutive patients with newly diagnosed PCNSL treated outside a clinical trial. Median age and ECOG Performance Status of considered patients were 62 years (range 28â78) and 2 (range 0â4). The overall response rate after MATRix was 79%. Nine (6%) treatment-related deaths were recorded. After a median follow-up of 27.4 months (95% confidence interval [CI] 24.4â31.9%), the two-year progression-free and overall survival were 56% (95% CI 48.4â64.9%) and 64.1% (95% CI 56.7â72.5%) respectively. Patients not eligible for the IELSG32 trial were treated with lower dose intensity and had substantially worse outcomes than those fulfilling inclusion criteria. This is the largest series of PCNSL patients treated with MATRix outside a trial and recapitulates the IELSG32 trial outcomes in the non-trial setting for patients who fit the trial criteria. These data underscore the feasibility and efficacy of MATRix as induction treatment for fit patients in routine practice
- âŠ